U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C20H31NO2.ClH
Molecular Weight 353.927
Optical Activity ( - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROFENINE HYDROCHLORIDE, (-)-

SMILES

Cl.CCN(CC)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2

InChI

InChIKey=WIELVDXKOYPANK-UHFFFAOYSA-N
InChI=1S/C20H31NO2.ClH/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5,7-8,11-12,18-19H,3-4,6,9-10,13-16H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H31NO2
Molecular Weight 317.4656
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Drofenine, product name Spasmo-Cibalgin (Novartis, Oman), is an antispasmodic/anticholinergic agent used for relaxing smooth muscle, treating dysmenorrhea, and relieving pain in the gastrointestinal tract, biliary passages, and urogenital tract. The possible therapeutic effect of drofenine is proposed by its activation of transient receptor potential vanilloid-3 (TRPV3), a member of the TRPV subfamily of TRP ion channels.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q8NET8
Gene ID: 162514.0
Gene Symbol: TRPV3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Spasmo Cibalgin

Approved Use

Unknown
Primary
Spasmo Cibalgin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Simultaneous determination of hydrochloride salts of adiphenine, diphenhydramine, ethyldiphenacetate, drofenine and promazine by ion-pair HPLC.
1983 Aug
Drofenine: A 2-APB Analogue with Greater Selectivity for Human TRPV3.
2014 Oct

Sample Use Guides

tablet
Route of Administration: Oral
Drofenine, was selective for TRPV3 in that activation of TRPA1, M8, V1, V2, and V4, which are known to be activated by the TRPV3 agonists 2-APB and/or carvacrol, was not observed at concentrations up to 1 mmol/L. A detectable change in TRPV3 activity was observed at concentrations as low as 30 μmol/L and increased in a concentration-dependent manner. At concentrations greater than 500 μmol/L, calcium flux exhibited some evidence of TRPV3 independence based on small and comparable responses in both native HEK-293 cells and other TRP channel overexpressing cell lines. The maximum change in cytosolic calcium (ΔF) for drofenine (EC50 = 207 μmol/L) was comparable to the known TRPV3 agonists 2-APB (EC50 = 78 μmol/L) and carvacrol (EC50 = 438 μmol/L).
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:24:30 GMT 2023
Edited
by admin
on Sat Dec 16 09:24:30 GMT 2023
Record UNII
8DHV447E9Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DROFENINE HYDROCHLORIDE, (-)-
Common Name English
BENZENEACETIC ACID, .ALPHA.-CYCLOHEXYL-, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE, (-)-
Systematic Name English
CYCLOHEXANEACETIC ACID, .ALPHA.-PHENYL-, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE, (-)-
Common Name English
Code System Code Type Description
CAS
3146-20-1
Created by admin on Sat Dec 16 09:24:30 GMT 2023 , Edited by admin on Sat Dec 16 09:24:30 GMT 2023
PRIMARY
FDA UNII
8DHV447E9Z
Created by admin on Sat Dec 16 09:24:30 GMT 2023 , Edited by admin on Sat Dec 16 09:24:30 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> ENANTIOMER
RACEMATE -> ENANTIOMER